Liver

Transform is an investigational study in patients with a 52-week, Randomized, Placebo-controlled, Double-blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52-week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness.

Primary disease category: 
Secondary disease category(ies): 

A randomized, double-blind, placebo-controlled phase 2b/3 study to evaluate the safety and efficacy of Saroglitazar Magnesium in subjects with Primary Biliary Cholangitis (PBC). 

Primary disease category: 
Secondary disease category(ies): 

Prospective, Multi-Center, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Saroglitazar Magnesium

Primary disease category: 
Secondary disease category(ies): 

This is a clinical trial designed to evaluate the performance of a multi-analyte blood test alone, ultrasound alone and the combination of both the multi-analyte blood test and ultrasound for the detection of HCC within a population that is at high risk for HCC due to liver cirrhosis.

Primary disease category: 
Secondary disease category(ies): 
Subscribe to RSS - Liver